oral coenzymeQ10: 60 children with community acquired pneumonia will receive oral coenzymeQ10 in capsule form at a dose of 100-200 mg/kg/day, as adjunct therapy to the usual pneumonia treatment till the recovery of the disease.
Study summary
The aim of this work is to assess the benefit of coenzyme Q10 supplementation, in addition to standard antibiotic and other supportive therapy, in the management of hospitalized children with community acquired pneumonia
Eligibility
Sex
ALL
Min age
2 Months
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria:
* All children aged 2 months -18 years with community acquired pneumonia diagnosed by signs and symptoms of CAP including; chest pain, dyspnea, tachypnea, or abnormal auscultatory findings plus focal findings on chest x ray indicating community acquired pneumonia
Exclusion Criteria:
* Children with immunodeficiency, chronic lung disease, malignancy, congenital lung anomalies, underlying disorder impacting respiration i.e. genetic, metabolic, neuromuscular disorders, children with CHD affecting the pulmonary blood flow.
Primary outcome measure(s)
Normalization of respiratory rate — 3 days
Normalization of temperature — 3 days
Normalization of oxygen saturation — 3 days
Normalization of Feeding Behavior Assessed by Oral Intake Tolerance — 3 days Normalization of feeding refusal will be assessed by evaluating the child's ability to tolerate age-appropriate oral feeding without refusal over a 3-day observation period.
Serum C-Reactive Protein (CRP) Level — 5 days Blood samples will be collected, and CRP concentration will be expressed in milligrams per liter (mg/L).
Serum Lactate Dehydrogenase (LDH) Level — 5 days LDH concentration will be reported in units per liter (U/L) from venous blood samples.
Prognostic Nutritional Index — 5 days
Systemic Immune-Inflammation Index — 5 days
Serum C-Reactive Protein to Albumin Ratio (CRP/Albumin Ratio) — 5 days The serum C-reactive protein to albumin ratio (CRP/albumin ratio) will be calculated as a single composite outcome measure using laboratory values obtained from the same blood sample.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.